Apr 19, 2021
Christian Sederberg and Barine Majewska will speak on cannabis law and psychedelics during the Cannalaw Summit on May 6, 2021.
There is a growing body of research into the therapeutic use of psilocybin, MDMA, and other entheogens, and it is inspiring policymakers, medical experts, and the public to reexamine drug policy at every level of government. Vicente Sederberg is committed to working with communities to develop sensible policy solutions that advance the public interest.
Vicente Sederberg has specialized in cannabis policy for over a decade, and we understand the complexities of transitioning a controlled substance from a prohibition model to a more nuanced system, in which it is decriminalized or regulated for research and other legal purposes. Our attorneys have extensive experience shaping decriminalization and regulatory policies in the U.S. and internationally, helping businesses, governments, advocates, and others understand and tactically navigate the interplay between local, state, and federal laws.
Laws, legal authorities, and avenues for reform vary from city to city and state to state, so we help our clients craft and execute impactful strategies and policy reform movements tailored to the unique legal and political considerations that apply in each jurisdiction. We also maintain strategic relationships with firms that have extensive experience navigating the complex federal and state regulatory landscapes surrounding the development of novel and emerging therapeutic products. Most notably, VS has formed an alliance with Kleinfeld, Kaplan & Becker LLP, a Washington, D.C.-based firm that concentrates on the regulation of products subject to the jurisdiction of the U.S. Food and Drug Administration (FDA) — including drugs and biologics, medical devices, dietary supplements, and controlled substances — as well as advertising law and other regulatory law governing consumer products and services. See the "Services" tab below for more details.
Assisting clients and advocacy organizations with the creation, drafting, and strategic implementation of local and state controlled substance policy reform measures
Assessing the risks for practitioners and other health care professionals in providing emerging therapies
Helping professional organizations shape ethical guidelines for practitioners in emerging therapies to set the standards for best practices
Providing corporate services for emerging therapies businesses, including forming benefit corporations
Protecting the religious freedoms and first amendment rights of organizations traditionally involved in entheogen practices
Navigating the complex federal and state regulations applicable to researching, manufacturing, storing, importing, exporting, and marketing of controlled substances
Complying with the U.S. Food and Drug Administration’s ever-evolving and -technical requirements for developing, researching, manufacturing, obtaining regulatory approvals and clearances for, and marketing novel and emerging therapeutic products
Issues presented by developing professional licensure and scope-of-practice requirements applicable to researchers and healthcare providers working with novel and emerging therapeutic products.
By Vicente Sederberg LLP
Dec 1, 2020
For our 10th anniversary, we take a look back at VS's history of leadership in cannabis law, the marijuana and hemp industries, and drug policy reform.
Aug 12, 2020
Watch this interview to learn more about the measure to allow Oakland residents to use entheogenic substances in community-based treatments and VS's involvement in drafting the proposed ordinance.
May 22, 2019
Vicente Sederberg was proud to assist the initiative proponents in drafting a measure that can mitigate the harms being caused by current state laws that treat psilocybin possession as a felony offense.